MetLife Investment Management’s Niagen Bioscience, Inc. Common Stock NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $434K | Hold |
30,126
| – | – | ﹤0.01% | 1742 |
|
|
2025
Q1 | $208K | Buy |
30,126
+3,567
| +13% | +$24.6K | ﹤0.01% | 2180 |
|
|
2024
Q4 | $141K | Buy |
26,559
+8,445
| +47% | +$44.8K | ﹤0.01% | 2470 |
|
|
2024
Q3 | $66.1K | Buy |
18,114
+5,115
| +39% | +$18.7K | ﹤0.01% | 2725 |
|
|
2024
Q2 | $35.5K | Buy |
+12,999
| New | +$35.5K | ﹤0.01% | 2821 |
|
|
2021
Q4 | – | Sell |
-5,907
| Closed | -$37K | – | 2563 |
|
|
2021
Q3 | $37K | Sell |
5,907
-12,993
| -69% | -$81.5K | ﹤0.01% | 2546 |
|
|
2021
Q2 | $186K | Buy |
18,900
+11,043
| +141% | +$109K | ﹤0.01% | 2214 |
|
|
2021
Q1 | $73.4K | Buy |
+7,857
| New | +$73.4K | ﹤0.01% | 2267 |
|